PureTech Health (NASDAQ:PRTC) (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.
PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies. Leading programs include LYT-100 (deupirfenidone), an anti-inflammatory/fibrotic agent in Phase 2 development for pulmonary and systemic indications; LYT-200, a novel antibody targeting tumor-associated antigens in colorectal cancer; and LYT-300, an enzyme-based therapy for primary hyperoxaluria. The company also maintains earlier-stage projects aimed at neurological conditions and immune-modulation.
Founded in 2005 by entrepreneur Daphne Zohar, PureTech Health is headquartered in Cambridge, Massachusetts, with additional operations in London. The company completed its initial public offering on the Nasdaq in 2020, building on a track record of strategic licensing and collaboration agreements with leading pharmaceutical partners. Its approach has generated several spin-out companies, enhancing shareholder value through focused clinical advancement and external partnerships.
Under the leadership of CEO and Founder Daphne Zohar, PureTech Health serves global markets through direct development and alliances. The organization emphasizes rigorous translational research, leveraging cross-disciplinary expertise to address high- unmet medical needs. By balancing in-house discovery with spin-out and partnership strategies, PureTech aims to deliver transformative therapies to patients worldwide.
